Intellectt Inc
Scientist, Cell Screening
Intellectt Inc, San Diego, California, United States, 92189
Genesis Therapeutics is pioneering artificial intelligence guided rationale drug design to alleviate patient need. Our lab in San Diego is looking to hire a scientist with experience in cellular techniques.
Specifically, we are seeking candidates to fill plate-based pharmacology, cell culture, cell engineering and drug discovery experimental plans for our rapidly advancing pipeline. Education requirements include a bachelor's or master's of science with specific focus in one or more of the following disciplines; cell signaling, cell physiology, protein biochemistry, cancer biology and immunology. This is a full-time position in a fast-paced biotech environment with a collegial group of high-level colleagues working towards well-defined goals.
What You Will Do
Design, optimize, develop, and routinely execute robust immuno-based screening assays (ELISA, MSD, HTRF, alphaLISA etc) and functional cell screening assays (Cyquant, CTG, Incucyte) for medium and high throughput assays in 2D and 3D formats.Experience routinely executing reporter cell assays.Program, validate, and operate liquid-handling automation (Biomek Liquid handler, Multidrop Combi, Integra Viaflo and Voyager) for 96-well and 384-well plate-based assays and use plate readers (Celigo, BioTeK Synergy) for data generation.Maintain, bank, and inventory multiple mammalian immortalized cancer cell lines (adherent & suspension) using proficient aseptic technique.Perform data analysis using Excel, Prism, and other software.Maintain electronic notebook entries and routine data reporting.Present work in various group, project team, and departmental meetings.What You Will Bring
A bachelor's with 5-6+ years’ industry experience or master's of science with some industry experience in biology. A doctorate with 1-2 years of experience.Individual will be highly motivated, highly productive, and goal-driven with experience in in vitro cell pharmacology, preferably from a preclinical small molecule oncology SAR drug discovery environment.A preferred candidate will have knowledge in the field of cell signaling, cell physiology, protein biochemistry, cancer biology and/or immunology, as well as method development, and scientific technologies.A preferred candidate will have experience using lab automation and high-throughput instrumentation, as well as ability to QC and analyze data.Individual must have high attention to detail to ensure reliable and reproducible data generation and can effectively communicate results.Required experience: mammalian tissue culture.We’d Be Thrilled If You Have Experience With
Western blot, RT-qPCR, and immunofluorescence techniques.Experience generating reporter cell lines.Experience performing target engagement studies (CETSA, NanoBRET, etc.).What We Offer
Competitive Pay.Stock Option Eligibility.401(k) Plan.Open PTO Policy.Paid Company Holidays.Free lunch and snacks at our offices.Health Care Plan, including Medical, Dental, and Vision, fully covered for the employees.About Genesis TherapeuticsGenesis Therapeutics is a pioneering AI Biotech company focusing on the discovery of novel drugs using unique approaches to both undrugged and underdeveloped targets with the goal of providing new treatments for patients with severe diseases.
Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. In addition, Genesis has announced two AI platform collaborations across a range of therapeutic areas with Genentech and Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. We’ve also been featured in Forbes 30u30 and in Forbes AI 50.
Genesis originated in graph machine learning research in Vijay Pande’s lab at Stanford, when it was joined by legendary drug hunters and biotech entrepreneurs (including Dr. Leonard Bell, founder and CEO of Alexion Pharmaceuticals, acquired by Astra Zeneca for $39Bn; and Peppi Prasit, storied chemist from Merck known for Vioxx, Arcoxia, Singulair, who then went on to found Amira Pharmaceuticals, acquired by BMS, and Inception Sciences). The company is making strong progress in expanding the domain of our AI technology with the advance of our pipeline of best-in-class and first-in-class programs, both internal targets and those in partnership with Genentech and Lilly.#J-18808-Ljbffr
Specifically, we are seeking candidates to fill plate-based pharmacology, cell culture, cell engineering and drug discovery experimental plans for our rapidly advancing pipeline. Education requirements include a bachelor's or master's of science with specific focus in one or more of the following disciplines; cell signaling, cell physiology, protein biochemistry, cancer biology and immunology. This is a full-time position in a fast-paced biotech environment with a collegial group of high-level colleagues working towards well-defined goals.
What You Will Do
Design, optimize, develop, and routinely execute robust immuno-based screening assays (ELISA, MSD, HTRF, alphaLISA etc) and functional cell screening assays (Cyquant, CTG, Incucyte) for medium and high throughput assays in 2D and 3D formats.Experience routinely executing reporter cell assays.Program, validate, and operate liquid-handling automation (Biomek Liquid handler, Multidrop Combi, Integra Viaflo and Voyager) for 96-well and 384-well plate-based assays and use plate readers (Celigo, BioTeK Synergy) for data generation.Maintain, bank, and inventory multiple mammalian immortalized cancer cell lines (adherent & suspension) using proficient aseptic technique.Perform data analysis using Excel, Prism, and other software.Maintain electronic notebook entries and routine data reporting.Present work in various group, project team, and departmental meetings.What You Will Bring
A bachelor's with 5-6+ years’ industry experience or master's of science with some industry experience in biology. A doctorate with 1-2 years of experience.Individual will be highly motivated, highly productive, and goal-driven with experience in in vitro cell pharmacology, preferably from a preclinical small molecule oncology SAR drug discovery environment.A preferred candidate will have knowledge in the field of cell signaling, cell physiology, protein biochemistry, cancer biology and/or immunology, as well as method development, and scientific technologies.A preferred candidate will have experience using lab automation and high-throughput instrumentation, as well as ability to QC and analyze data.Individual must have high attention to detail to ensure reliable and reproducible data generation and can effectively communicate results.Required experience: mammalian tissue culture.We’d Be Thrilled If You Have Experience With
Western blot, RT-qPCR, and immunofluorescence techniques.Experience generating reporter cell lines.Experience performing target engagement studies (CETSA, NanoBRET, etc.).What We Offer
Competitive Pay.Stock Option Eligibility.401(k) Plan.Open PTO Policy.Paid Company Holidays.Free lunch and snacks at our offices.Health Care Plan, including Medical, Dental, and Vision, fully covered for the employees.About Genesis TherapeuticsGenesis Therapeutics is a pioneering AI Biotech company focusing on the discovery of novel drugs using unique approaches to both undrugged and underdeveloped targets with the goal of providing new treatments for patients with severe diseases.
Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. In addition, Genesis has announced two AI platform collaborations across a range of therapeutic areas with Genentech and Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. We’ve also been featured in Forbes 30u30 and in Forbes AI 50.
Genesis originated in graph machine learning research in Vijay Pande’s lab at Stanford, when it was joined by legendary drug hunters and biotech entrepreneurs (including Dr. Leonard Bell, founder and CEO of Alexion Pharmaceuticals, acquired by Astra Zeneca for $39Bn; and Peppi Prasit, storied chemist from Merck known for Vioxx, Arcoxia, Singulair, who then went on to found Amira Pharmaceuticals, acquired by BMS, and Inception Sciences). The company is making strong progress in expanding the domain of our AI technology with the advance of our pipeline of best-in-class and first-in-class programs, both internal targets and those in partnership with Genentech and Lilly.#J-18808-Ljbffr